Lege Artis Medicinae

[A NEW DISCIPLINE IN THE CENTER OF MEDICAL RESEARCH AND CLINICAL PRACTICE - THOUGHTS ON BIOINFORMATICS]

FALUS ANDRÁS, BERKE Tamás, ORTUTAY Csaba Péter, SUHAI György

JANUARY 21, 2004

Lege Artis Medicinae - 2004;14(01)

[Bioinformatics is one of the most important element of genomic research revolutionising biomedical science. This review describes the phenomena of genomic variance and comparative genomics. Briefly, the review summarises the identification procedure of new genes and gene expression patterns highly important in diagnostics. Bioinformatic procedures make possible the rapid detection of pathogens and have principal role in molecular drug design technologies.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[GENDER ASSOCIATED DIFFERENCES IN THE PROGRESSION OF RENAL DISEASES]

MÜLLER Veronika, SZABÓ Attila

[Increasing evidence suggests an important role of gender in the incidence, progression and different therapeutic possibilities of several diseases. Recent data demonstrated gender associated differences in the development and progression of chronic renal diseases. Present work reviews sexual dimorphism in different chronic renal diseases, summarizes underlying pathophysiological processes and therapeutic possibilities focusing on the role of gender. New evidences may present the base of gender based therapies in the future.]

Lege Artis Medicinae

[LEGIONNAIRES’ DISEASE]

ROJKÓ Lívia

[Legionellae are important causative agents of nosocomial and community acquired pneumonias, the prevalence varying between 2-30%. The number of verified infections are increasing from year to year, which may be the consequence of the more sensitive and commonly applied laboratorical methods or can be explained by the spread of non-natural living environments created by humans. The outcome of Legionella infections are strongly determined by the host immune system, the comorbidities, the time to the diagnosis made and the initiated treatment. This review focuses on the various clinical manifestations of the Legionella infections, and summarises the diagnostic criteria and therapeutic methods in practice.]

Lege Artis Medicinae

[LOCAL INEQUALITIES IN THE UTILIZATION OF SPECIAL HOME NURSING IN THE SOUTH-TRANSDANUBIAN REGION]

BONCZ Imre, SÁNDOR János, OLÁH András, BETLEHEM József, SEBESTYÉN Andor, KISBENEDEKNÉ Gulyás Kinga, DÓZSA Csaba

[INTRODUCTION - The aim of this study is to analyse the local inequalities in the access and utilization of special home nursing within Hungary focusing on the South-Transdanubian Region. DATA AND METHODS - In the first part of the study we compared the indicators of the access and utilizations of special home nursing at national and county level. In the second part of the analyses we made a detailed analyses of utilization data of home nursing in the three counties (Baranya, Somogy, Tolna) of the South- Transdanubian Region of Hungary. Data is derived from the financial database of the National Health Insurance Fund of Hungary for the period 1998-2002. RESULTS - The access of population to the special home nursing increased from 83,8% (1998) to 95,1% (2002). The utilization rate increased from 74,8% (1998) to 84,1% (2002). Within the South-Transdanubian Region we found significant local inequalities in the utilization of services (number of cases, number of visits), which were represented by the tools of geographical information system. CONCLUSIONS - There have been significant differences in the access and utilization of home nursing with remarkable within country inequalities.]

Lege Artis Medicinae

[SCIENTIFIC DIGEST]

Lege Artis Medicinae

[THE METABOLIC SYNDROME CLINICAL APPEARANCE, DIAGNOSIS, PATHOMECHANISM]

KÉKES Ede, CZURIGA István

[The metabolic syndrome has gone by several names over the past two decades. The diagnostic criteria were proposed by the ATP III of NCEP in 2001 and were accepted by European Society of Cardiology and European Society of Hypertension in 2003. The criteria (abnormal waist rate, HDLcholesterol, triglyceride, blood pressure and fasting glucose) are listed and the presence of any three of these factors is considered sufficient for diagnosis. The prevalence of syndrome affects about a quarter of the Hungarian population with hypertension. The metabolic syndrome is associated with premature cardiovascular morbidity and mortality including an excess of sudden deaths. According to the recent literature data the main component of the syndrome, the obesity, especially with abdominal fat distribution is associated with hypertension, hyperinsulinemia and insulin resistance with related abnormalities of carbohydrate and lipid metabolism. The low HDL cholesterol, high triglyceride level and the small, dense LDL cholesterol particles are the parts of lipid component of syndrome. A variety of environmental (obesity, smoking, physical inactivity) and genetic factors (genetic mutations of lipoprotein lipase, hepatic lipase, CETP and PPA receptors) and the impaired FFA metabolism have all been related to lipid abnormalities. Sympathetic hyperfunction participates in the pathogenesis and complications of metabolic syndrome. Possible factors augmenting sympathetic activation include alterations of insulin, leptin, FFA, cytokines, sleep apnoe. Other important factors as the endocrin concept, the hypothalamus-hypophysis- adrenal axis, endothelial dysfunction are discussed. The impaired muscle insulin stimulated glycogen synthesis (FFA induced GLUT-4 inhibition) is the major cellular factor of insulin resistance. There is a continuous process from the insulin resistance state (with hyperinsulinemia) into the 2T diabetes mellitus (with hypoinsulinemia).]

All articles in the issue

Related contents

Clinical Oncology

[Gene-expression profiles in adjuvant treatment of early breast cancer]

PAJKOS Gábor

[Breast cancer is a heterogeneous disease with different subtypes having a distinct biological, molecular, and clinical course. Assessments of standard clinical and pathological features have traditionally been used to determine the use of adjuvant systemic therapy in early-stage breast cancer; however, the ability to identify those who will benefi t from adjuvant chemotherapy remains a challenge, leading to over treatment of some patients. Risk stratifi cation of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of seven multi-gene classifi ers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test’s analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.]

Lege Artis Medicinae

[NON-CODING GENOME AND MICRO-RNAS: A NEW CHAPTER IN THE HISTORY OF GENETICS]

MOLNÁR Viktor, BAKOS Beáta, HEGYESI Hargita, FALUS ANDRÁS

[Since the discovery of the function of the deoxyribonucleic acid, research for decades focused on studying the protein coding regions in ever increasing details. At the same time, non-coding DNA sequences, which represent 98% of the genome, were considered an evolutionary byproduct, or junk DNA. Today, however, the large families of short, untranslated ribonucleic acid sequences, such as short interfering RNA (siRNA), microRNA, rasiRNA or piRNA, revolutionize our knowledge on gene regulation. The review presents these short RNA molecules, and describes their formation and functions. The authors place special focus on the recently discovered microRNAs, a class of 21-24 nucleotides long RNA molecules that are involved in the regulation of their target’s amount by annealing to the corresponding messenger RNA. The genes of microRNAs are often localized to certain fragile sites of the genome that have been described to be involved in a number of tumours. Thus, it is not surprising that after the discovery of microRNAs the relationship of altered microRNA pattern and cancer has soon become the focus of research.]

Lege Artis Medicinae

[NEW PROSPECTS IN MEDICINE BY THE APPLICATION OF BIOTECHNOLOGICAL METHODS]

KOSZTOLÁNYI György

[The recent completion of the sequence of the human genome - thanks to the developments in biotechnology - has increased interest in genetics, but confusion remains about the role of genetic information in the medical practice. The role of genomics (a term coined only 15 years ago) in medicine is even more confusing. This review summarizes briefly the most important advances relating to the robust development in biotechnology, by which the practice of medicine has entered an era where the individual patient’s genome could help to determine the optimal approach to care, whether it is preventive, diagnostic, or therapeutic.]

Lege Artis Medicinae

[Human genome project]

SASVÁRI-SZÉKELY Mária

[The main goal of the Human Genom Project is to reveal the complete structure of the human DNA, involving the sequence determination of the three billion basepairs. The program was launched in 1990, executed in laboratories of the public sector in several countries. Results of this project are made public on the Internet. In 1998 a private sector company, Celera, was founded with the same goal. In 2001 both projects announced the accomplishment of the first draft of the Human Genome. A whole issue of Nature and Science magazine was devoted to present the first results of their findings. According to the results less than one percent of the genetic information is transcribed to proteins. The estimated number of genes was also lower than expected (30-40 thousand, which number recently increased to 40-60 thousand). Based on these findings, human complexity should be ascribed to the variability of the information units (domains) rather than to the number of genes. Once the complete sequence of the humane genome is accomplished, the ’pre-genomic era’ will be over and the ’post-genomic era’ will begin, dealing with understanding the genetic information, annotating the genes and mapping the genetic variability of people.]

Clinical Oncology

[Clinical role of multigenic prognostic tests in breast cancer therapy]

GYŐRFFY Balázs

[Current clinical practice for breast cancer originates in “evidence based medicine”. In this, each tumor receives a therapy optimal for a given patient population - which might not be optimal for each individual patient. Multigenic tests determining expression of a set of genes can provide additional support in this decision process. Two such tests (MammaPrint and Prosigna) have already received FDA clearance. A number of additional test are commercially available (IHC4, Oncotype DX, EndoPredict, BCI). A common property of these assays is their utility in estrogen receptor positive early breast cancer. The main clinical problem answered by them is the necessity of adjuvant chemotherapy. To date, no reliable algorithm has been identifi ed capable to pinpoint the most effective chemotherapy combination for a given patient. Furthermore, there is no trustworthy test for triple negative breast cancer. The assays utilize different technologies (immunohistochemistry, gene chips, RT-PCR) and a discrepant list of genes - these result in discordance of the predictions for the individual patient. Despite these shortcomings, multigenic tests quickly gained foothold in breast cancer therapy decision process. Their utility is supported by the cost reduction for the health care providers by lowering the number of patients eligible for chemotherapy.]